EG 017
Alternative Names: EG-017Latest Information Update: 20 Nov 2023
At a glance
- Originator GeneScience Pharmaceuticals
- Class Antineoplastics; Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dry eyes; Stress incontinence
- Phase I HER2 negative breast cancer
Most Recent Events
- 20 Sep 2023 Phase-II clinical trials in Dry eyes in China (unspecified route) (NCT06133166)
- 08 Mar 2023 Phase-I clinical trials in HER2-negative-breast-cancer (Late-stage disease, Metastatic disease, Recurrent) in China (unspecified route) (NCT05673694)
- 06 Jan 2023 GeneScience Pharmaceuticals plans a phase I trial for HER2-negative-breast-cancer (Late-stage disease, Metastatic disease, Recurrent)in China, in February 2023 (NCT05673694)